{"title":"新发转移性乳腺癌的原发肿瘤手术:改变游戏规则还是误解?","authors":"Gianluca Franceschini","doi":"10.1007/s10238-024-01552-4","DOIUrl":null,"url":null,"abstract":"<p><p>The study titled \"Primary tumor surgery in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium\" opens an important discussion about the potential role of surgery in the treatment of de novo MBC; although the results are promising, they should be interpreted with caution given the limitations of the study design. The question remains whether surgery is truly a game-changer for all patients or whether its benefits are more nuanced depending on individual patient factors and disease characteristics. As the oncology community continues to explore this question, a modern breast surgeon should emphasize the importance of further prospective trials and personalized treatment strategies that consider not only surgery but also the growing arsenal of available systemic therapies.</p>","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"26"},"PeriodicalIF":3.2000,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11698822/pdf/","citationCount":"0","resultStr":"{\"title\":\"Primary tumor surgery in de novo metastatic breast cancer: Game-changer or misinterpretation?\",\"authors\":\"Gianluca Franceschini\",\"doi\":\"10.1007/s10238-024-01552-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The study titled \\\"Primary tumor surgery in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium\\\" opens an important discussion about the potential role of surgery in the treatment of de novo MBC; although the results are promising, they should be interpreted with caution given the limitations of the study design. The question remains whether surgery is truly a game-changer for all patients or whether its benefits are more nuanced depending on individual patient factors and disease characteristics. As the oncology community continues to explore this question, a modern breast surgeon should emphasize the importance of further prospective trials and personalized treatment strategies that consider not only surgery but also the growing arsenal of available systemic therapies.</p>\",\"PeriodicalId\":10337,\"journal\":{\"name\":\"Clinical and Experimental Medicine\",\"volume\":\"25 1\",\"pages\":\"26\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-01-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11698822/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Experimental Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10238-024-01552-4\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10238-024-01552-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Primary tumor surgery in de novo metastatic breast cancer: Game-changer or misinterpretation?
The study titled "Primary tumor surgery in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium" opens an important discussion about the potential role of surgery in the treatment of de novo MBC; although the results are promising, they should be interpreted with caution given the limitations of the study design. The question remains whether surgery is truly a game-changer for all patients or whether its benefits are more nuanced depending on individual patient factors and disease characteristics. As the oncology community continues to explore this question, a modern breast surgeon should emphasize the importance of further prospective trials and personalized treatment strategies that consider not only surgery but also the growing arsenal of available systemic therapies.
期刊介绍:
Clinical and Experimental Medicine (CEM) is a multidisciplinary journal that aims to be a forum of scientific excellence and information exchange in relation to the basic and clinical features of the following fields: hematology, onco-hematology, oncology, virology, immunology, and rheumatology. The journal publishes reviews and editorials, experimental and preclinical studies, translational research, prospectively designed clinical trials, and epidemiological studies. Papers containing new clinical or experimental data that are likely to contribute to changes in clinical practice or the way in which a disease is thought about will be given priority due to their immediate importance. Case reports will be accepted on an exceptional basis only, and their submission is discouraged. The major criteria for publication are clarity, scientific soundness, and advances in knowledge. In compliance with the overwhelmingly prevailing request by the international scientific community, and with respect for eco-compatibility issues, CEM is now published exclusively online.